--- title: "603669.SH (603669.SH) — Related News" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/603669.SH/news.md" symbol: "603669.SH" name: "603669.SH" parent: "https://longbridge.com/en/quote/603669.SH.md" datetime: "2026-05-21T01:01:05.437Z" locales: - [en](https://longbridge.com/en/quote/603669.SH/news.md) - [zh-CN](https://longbridge.com/zh-CN/quote/603669.SH/news.md) - [zh-HK](https://longbridge.com/zh-HK/quote/603669.SH/news.md) --- # 603669.SH (603669.SH) — Related News ### [Lionco: Application to postpone the disclosure of the 2025 annual report and the first quarter report of 2026 to April 29, 2026](https://longbridge.com/en/news/283967710.md) *2026-04-24T09:12:47.000Z* > Lionco announced that the company was originally scheduled to disclose the "2025 Annual Report" and the "2026 First Quar ### [Lionco: Cancel 8.9159 million shares](https://longbridge.com/en/news/283475774.md) *2026-04-21T10:04:29.000Z* > Lionco announced that 8.9159 million shares in the company's repurchase special securities account will be canceled, wit ### [](https://longbridge.com/en/news/283423182.md) *2026-04-21T01:40:16.000Z* > The A-share pharmaceutical sector was active at the beginning of the trading session, with YIBAI PHARMACEUTICAL hitting ### [](https://longbridge.com/en/news/280259034.md) *2026-03-24T05:07:49.000Z* > The A-share biopharmaceutical sector rose again in the afternoon, with Lionco hitting the daily limit, followed by DiZhe ### [Lionco: Controlling shareholder releases pledge on 49.6596 million shares](https://longbridge.com/en/news/275566963.md) *2026-02-11T07:35:47.000Z* > Lionco announced that its controlling shareholder, Lionco Holdings, will release the pledge of 49.6596 million shares on ### [Lionco: Revenue of 365 million yuan in 2025, with a net loss forecast of 127 million yuan](https://longbridge.com/en/news/275093972.md) *2026-02-06T08:12:09.000Z* > Lionco expects its operating revenue to be approximately 365 million yuan in 2025, a year-on-year decrease of 3.89%; aft ### [Lionco: Expected annual net profit loss of 127 million yuan in 2025](https://longbridge.com/en/news/273496442.md) *2026-01-23T09:44:14.000Z* > Lionco announced that it expects a net profit loss of 127 million yuan for the year 2025, compared to a loss of 131 mill ### [Lionco: Subsidiary Lionco Pharmaceutical's product, injectable cefazolin sodium, is expected to be selected for national centralized drug procurement](https://longbridge.com/en/news/263233220.md) *2025-10-29T07:58:42.000Z* > Lionco announced that its wholly-owned subsidiary Lionco Pharmaceutical's injectable cefazolin sodium product is expecte ### [](https://longbridge.com/en/news/254354349.md) *2025-08-25T02:14:10.000Z* > The A-share CRO concept sector has seen a surge, with Lionco hitting the daily limit, MeHow rising over 10%, and Haoyuan ### [](https://longbridge.com/en/news/250504807.md) *2025-07-29T02:39:18.000Z* > The A-share CRO concept continues to strengthen, with PHARMABLOCK rising over 15%, and HITECK, TIGERMED, JOINN, Lionco,